REGENERON PHARMACEUTICALS, INC. REGN
Last close
827.72
2026-09-04
Market cap
$85.09B
estimated share count
52-week range
541.00 - 859.34
Valuation FY2025 figures against the last close
P/S5.9x
P/E20.0x
P/FCF20.9x
EV/EBITDA19.0x
Dividend yield0.4%
Diluted EPS41.48
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B |
| Cost of revenue | — | — | — | — | — | — | $402.8M | $237.5M | $202.5M | $194.6M |
| Gross profit | — | — | — | — | — | — | $6.15B | $4.91B | $5.67B | $4.67B |
| R&D | $5.85B | $5.13B | $4.44B | $3.59B | $2.86B | $2.65B | $2.45B | $1.47B | $2.08B | $2.05B |
| SG&A | $2.70B | $2.95B | $2.63B | $2.12B | $1.82B | $1.35B | $1.34B | $1.13B | $1.32B | $1.18B |
| Total operating expenses | $10.77B | $10.21B | $9.07B | $7.43B | $7.12B | $4.92B | $4.35B | $2.61B | $3.79B | $3.53B |
| Operating income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B | $3.58B | $2.21B | $2.53B | $2.08B | $1.33B |
| Interest expense | $43.8M | $55.2M | $73.0M | $59.4M | $57.3M | $56.9M | $30.2M | $28.2M | $25.1M | $7.2M |
| Pre-tax income | $5.23B | $4.78B | $4.20B | $4.86B | $9.33B | $3.81B | $2.43B | $2.55B | $2.08B | $1.33B |
| Income tax | $725.8M | $367.3M | $245.7M | $520.4M | $1.25B | $297.2M | $313.3M | $109.1M | $880.0M | $434.3M |
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $895.5M |
| EPS, basic | 43.07 | 40.90 | 37.05 | 40.51 | 76.40 | 32.65 | 19.38 | 22.65 | 11.27 | 8.55 |
| EPS, diluted | 41.48 | 38.34 | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 | 21.29 | 10.34 | 7.70 |
| Shares, diluted (wtd. avg.) | $108.6M | $115.1M | $113.7M | $113.5M | $112.2M | $115.1M | $114.6M | $114.8M | $115.9M | $116.3M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.12B | $2.49B | $2.73B | $3.12B | $2.90B | $2.21B | $1.63B | $1.48B | $825.2M | $547.7M |
| Short-term investments | $5.49B | $6.52B | $8.11B | $4.64B | $2.81B | $1.39B | $1.60B | $1.34B | $596.8M | $503.5M |
| Receivables | $5.74B | $6.21B | $5.67B | $5.33B | $6.04B | $4.11B | $2.10B | $1.72B | $1.54B | $1.34B |
| Inventory | $3.20B | $3.09B | $2.58B | $2.40B | $1.95B | $1.92B | $1.42B | $1.15B | $726.1M | $399.4M |
| Total current assets | $18.02B | $18.66B | $19.48B | $15.88B | $14.01B | $9.78B | $7.69B | $6.45B | $4.33B | $3.18B |
| Property, plant and equipment | — | — | — | — | — | — | — | $2.58B | $2.36B | $2.08B |
| Other intangibles | $1.26B | $1.15B | $1.04B | $915.5M | $6.7M | — | — | — | — | — |
| Total assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B | $14.81B | $11.73B | $8.76B | $6.97B |
| Accounts payable | $939.0M | $789.5M | $606.6M | $589.2M | $564.0M | $475.5M | $418.1M | $218.2M | $178.2M | $879.1M |
| Total current liabilities | $4.37B | $3.94B | $3.42B | $3.14B | $3.93B | $2.70B | $2.10B | $1.44B | $1.14B | $1.24B |
| Long-term debt | $1.99B | $1.98B | $1.98B | $1.98B | $1.98B | $1.98B | $0 | — | — | — |
| Total liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B | $6.14B | $3.72B | $2.98B | $2.62B | $2.52B |
| Retained earnings | $35.80B | $31.67B | $27.26B | $23.31B | $18.97B | $10.89B | $7.38B | $5.25B | $2.95B | $1.75B |
| Total equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B | $11.03B | $11.09B | $8.76B | $6.14B | $4.45B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.98B | $4.42B | $4.59B | $5.01B | $7.08B | $2.62B | $2.43B | $2.20B | $1.31B | $1.49B |
| Depreciation and amortisation | $543.7M | $482.9M | $421.0M | $341.4M | $286.2M | $235.9M | $210.3M | $148.2M | $145.5M | $104.7M |
| Stock-based compensation | $993.7M | $982.8M | $885.0M | $725.0M | $601.7M | $432.0M | $464.3M | $427.4M | $507.3M | $559.9M |
| Capital expenditure | $898.4M | $755.9M | $718.6M | $590.1M | $551.9M | $614.6M | $429.6M | $383.1M | $272.6M | $511.9M |
| Investing cash flow | -$629.1M | -$2.47B | -$3.19B | -$3.78B | -$5.38B | -$70.6M | -$2.03B | -$1.46B | -$1.01B | -$1.05B |
| Financing cash flow | -$3.72B | -$2.20B | -$1.79B | -$1.01B | -$1.01B | -$1.97B | -$252.1M | -$77.1M | -$24.4M | -$700.5M |
| Dividends paid | $370.3M | $0 | $0 | — | — | — | — | — | — | — |
| Buybacks | $3.44B | $2.60B | $2.23B | $2.08B | $1.65B | $5.85B | $275.9M | $4.4M | $0 | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001308179-26-000340.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |